---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-23-000045"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:59:34.966268+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics Q2 revenue $146.8M (+28% YoY); raises FY2023 guidance to $600-620M

## Summary
- Revenue $146.8M in Q2, +28% YoY from $114.6M.
- Gross margin 68% vs 76% prior year, down on product mix from new launches.
- Net loss $62.4M vs $64.5M YoY; stock-based compensation expense $45.7M.
- Raises FY2023 revenue guidance to $600-620M from prior $590-610M, 16-20% growth.
- Accelerated Xenium in situ platform momentum; launched Visium CytAssist Gene & Protein Expression assay.

## SEC filing metadata
- accession: 0001770787-23-000045
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000045/0001770787-23-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000045/txg-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-23-000045
- JSON: https://secwatch.observer/filing/0001770787-23-000045.json
- Plain text: https://secwatch.observer/filing/0001770787-23-000045.txt

## Key facts
- Earnings Releases
  10x Genomics, Inc. reported the second quarter ended June 30, 2023 results: revenue $146.8 million, net income Net loss was $62.4 million. Guidance raised.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $146.8 million
  - Net income: Net loss was $62.4 million
  - Guidance: raised
  - Result: reported results
  source text: Revenue was $146.8 million for the second quarter of 2023, a 28% increase from $114.6 million for the corresponding prior year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000045/0001770787-23-000045-index.htm
- Earnings Releases
  10x Genomics, Inc. reported full year 2023 results: revenue $600 million to $620 million. Guidance raised.
  - Period: full year 2023
  - Revenue: $600 million to $620 million
  - Guidance: raised
  - Result: guidance update
  source text: 10x Genomics is raising its full year 2023 revenue guidance and now expects revenue in the range of $600 million to $620 million, representing 16% to 20% growth over full year 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000045/0001770787-23-000045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.